Rights Outside the Field. 4Life shall have no rights, and Clene hereby reserves all rights, to the Licensed Products, Licensed Patents and Licensed Know How outside the Field.
Rights Outside the Field. ViroPharma shall not develop or commercialize, or grant or convey to any third party any rights to develop or commercialize, the Compound and/or Products for use outside the Field without the prior written consent of Schering. Any such written consent granted by Schering shall include the terms under which such development or commercialization may proceed.
Rights Outside the Field. Except as specifically set forth herein, each party shall have the sole and exclusive right, including rights under its own interests in any Joint Technology and any Patent Rights thereon and rights to grant sublicenses thereunder, to develop, have developed, make, have made, use, distribute for sale, sell, offer for sale and import any products which are derived from its Compounds other than Antibacterial Products listed on Schedule I for all uses outside the Field.
Rights Outside the Field. XOMA and Chiron each acknowledge and agree that the rights and licenses granted to XOMA by Chiron, and the rights and licenses granted to Chiron by XOMA, pursuant to the terms and conditions of this Agreement are only as to the Field. In addition, XOMA and Chiron each agree that (i) Collaboration Products may be developed and commercialized outside the Field, (ii) XOMA, or an Affiliate or a licensee of XOMA, may develop and commercialize an Opt-Out Product for use outside the Field in the event that Chiron is the Opting-Out Party, (iii) Chiron, or an Affiliate or a licensee of Chiron, may develop and commercialize an Opt-Out Product in the event that XOMA is the Opting-Out Party for use outside the Field, and (iv) Chiron, or an Affiliate or a licensee of Chiron, may develop and commercialize a product derived from a Human Engineered™ Antibody generated from a Dismissed Target pursuant to Section 3.4 for use outside the Field; provided that, with respect to (ii), (iii) and (iv) above, [*]. For purposes of clarification, no consideration, other than as set forth in this Agreement for Collaboration Products, Opt-Out Products, and products derived from a Human Engineered™ Antibody generated from a Dismissed Target, whether in the form of fees or royalties, will be due or payable with respect to commercialization of such a product outside the Field.
Rights Outside the Field. Cypress shall offer to Organon a first right to negotiate co exclusive joint research and development of Development Candidates and Approved Products in any field, outside the Field, with the exception of the Animal Health Field, for which Cypress Controls Patents claiming the use of Development Candidates or Approved Products in such field on terms and subject to conditions to be separately negotiated by the parties. In the event that [...***...] Cypress shall offer ***Confidential Treatment Requested the terms for such collaboration to Organon before offering such opportunity to any Third Party. Organon shall have 60 days in which to respond to such offer. If Organon provides written notice to Cypress expressing interest in such rights during such 60 day period, the parties shall negotiate the terms for any such collaboration in good faith; provided, however, that, if the parties have not reached agreement on the principal terms of such collaboration within [...***...] after Organon’s notice expressing its interest, then Cypress shall have no further obligation to Organon with respect to research and development of Development Candidates and Approved Products in such field and may pursue such activities alone or with one or more Third Parties.
Rights Outside the Field. Subject always to (a) Salix’s interest in the Salix Technology Rights, the Other Forms Claims of the [*] Patent Family and the Joint Technology, and (b) Alfa’s interest in the Alfa Technology Rights, the [*] Claims and the Joint Technology, and without implying any license or other grant or transfer of rights other than those explicitly set forth herein, in the Supply Agreements or in the Trademark License Agreements, except for the restriction on unauthorized sales set forth in Section 5.1, nothing set forth in this Agreement is intended to (y) place any restrictions on Alfa and its Affiliates from Exploiting the Alfa Technology Rights for any purpose outside the Field in any geographic territory or (z) place any restrictions on Salix and its Affiliates from Exploiting the Salix Technology Rights for any purpose outside the Field in any geographic territory (subject to Alfa’s exclusive rights granted hereunder with respect to the [*] Patent Family). Not to limit the generality of the foregoing, Salix acknowledges that Alfa has Developed or will Develop formulations of the Compound which may be useful for [*] and also [*] uses, which are outside of the Field. Salix agrees that the activities which Alfa or its licensees undertake in the fields of [*] and [*] applications do not adversely affect Salix’s ability to Exploit the rights granted to it in this Agreement.
Rights Outside the Field. Warner may develop and commercialize Compounds for indications outside the Field, and conduct research and development of Compounds for indications outside the Field using Disease Genes and Non-Disease Genes, as follows:
Rights Outside the Field. The co-exclusive rights of the Parties hereunder will extend to all indications outside the Field with respect to PT-141, including the use of PT-141 in combination with one or more other actives and in any formulation including, without limitation, in any delivery method. In the event King or Palatin make any invention or discovery with respect to PT-141 outside the Field, such new invention or discovery shall be part of the Collaboration and the rights of the Parties with respect thereto shall be subject to the terms and conditions hereof. Any activities of the Parties with respect to PT-141 outside the Field shall only be undertaken by the Parties pursuant to their mutual consent and pursuant to the framework established by the Collaboration and this Agreement. Neither Party shall have any right to, and neither Party shall, undertake any research, development, manufacture or commercialization of PT-141 outside the Field outside the Collaboration, either on its own or with any third party.
Rights Outside the Field. Each of Sumitomo and CombiChem shall have rights to make, have made, use, have used, sell, have sold and import Inactive Compounds outside the Field. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Rights Outside the Field. LICENSEE hereby grants to MONSANTO the same rights of first refusal for uses of the Compounds outside the Field as set forth in Article 4.1 hereof if MONSANTO can conclusively show that any such uses outside the Field were developed using any of the Compound or the synthesis intermediates provided by MONSANTO to LICENSEE pursuant to Article 3.5 hereof, failing which MONSANTO shall have no rights with respect to uses of the Compounds outside the Field owned by LICENSEE. The terms of Articles 4.1 are incorporated by reference herein mutatis mutandis.
